niddk-tirzepatide Compounded Tirzepatide NYC 𝗛𝗼𝗻𝘅𝗶® 𝗡𝗜𝗗𝗗𝗞-𝗧𝗶𝗿𝘇𝗲𝗽𝗮𝘁𝗶𝗱𝗲 𝗡𝗮𝗻𝗼 𝗠𝗶𝗰𝗿𝗼𝗻𝗲𝗲𝗱𝗹𝗲 𝗣𝗮𝘁𝗰𝗵

Your health journey is our passion, and these stories inspire us to continue providing exceptional care

Preliminary results from the SURPASS-J-mono study in Japanese patients with T2D who were either therapy nave or on an antidiabetic monotherapy showed a head-to-head comparison of a tirzepatide treatment compared to therapy with the GLP-1RA dulaglutide at a dose of 0.75 mg (76)

a hoarse voice

Important safety information includes a boxed warning for thyroid C-cell tumors (contraindicated in patients with personal/family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2) and warnings for pancreatitis, gallbladder disease, acute kidney injury, and hypoglycemia risk when used with insulin or sulfonylureas